(Incorporated in the Cayman Islands)

We are a newly established blank check company. We intend to focus our search for an acquisition target on the life sciences sector. The search will be global – not restricted to any geographic area. 

We intend to evaluate and target companies that aim to improve human health, including those in therapeutics, diagnostics, genomics, precision medicine, life science tools, research services, biomanufacturing and related subsectors, where our management team has extensive investment and operational experience.

Dr. Gbola Amusa has served as our CEO and as a member of our board of directors since March 2026. Dr. Amusa has more than 25 years of experience evaluating, investing in, financing, operating, and advising life sciences companies across public and private markets, including as an equity research analyst, investment banker, public company director and audit committee member, operating executive, and special purpose acquisition company executive and sponsor. Earlier in his career, Dr. Amusa held senior leadership roles in healthcare equity research at UBS from 2007 to 2013 and Sanford Bernstein from 2003 to 2007, including serving as Managing Director, Head of European Pharma Research, and Global Pharma & Biotech Coordinator at UBS and Head of European Pharma research at Sanford Bernstein. He began his career in healthcare investment banking at Goldman Sachs & Co. LLC. Dr. Amusa holds an M.D. from Washington University School of Medicine, an M.B.A. from the University of Chicago Booth School of Business, and a B.S.E. in Biomedical Engineering from Duke University.

Guy Barudin has served as our CFO since July 2026. Mr. Barudin has more than 25 years of experience in corporate finance, capital markets, strategic transactions, public company leadership, and special purpose acquisition companies. Mr. Barudin currently serves as a Managing Director at Chardan, where he has provided clients with investment banking, capital markets, and strategic advisory activities since February 2019 in a variety of transactions including SPAC business combinations. Mr. Barudin served as Chief Operating Officer of Chardan Healthcare Acquisition 2 from March 2020 to September 2021, when it completed its business combination with Renovacor, and previously served as Chief Financial Officer and Chief Operating Officer of Terrapin 3 Acquisition Corp. (“Terrapin 3 Acquisition”), a publicly traded SPAC, from December 2013 through its business combination with Yatra Online, Inc. (Nasdaq: YTRA) (“Yatra”) in December 2016. From 2007 to 2019, Mr. Barudin served as Managing Director of Terrapin Partners, a private investment firm. Earlier in his career, Mr. Barudin held finance, business development, and strategic transaction roles at Medco Health Solutions and Mastercard and worked in corporate finance at Merrill Lynch, PaineWebber, and Dillon Read. Mr. Barudin received an M.S. from the Massachusetts Institute of Technology Sloan School of Management and a B.S.E. in Civil Engineering with honors from Princeton University.

(Note: Rainier Acquisition Corp. filed its S-1 for its SPAC IPO on Aug. 6, 2026, and disclosed the terms: 7.5 million units at $10.00 each to raise $75 million. Each unit consists of one share and one right to acquire one-fourth (1/4th) of a share upon the consummation of its initial business combination.)